Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Lawson

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical Immunology (Orlando, Fla.)|August 31, 2015
Interleukin-7 is required for CD4(+) T cell activation and autoimmune neuroinflammationBrian R Lawson, Rosana Gonzalez-Quintial, Theodoros Eleftheriadis, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2009
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupusDwight H Kono, M Katarina Haraldsson, Brian R Lawson, et al.
Angewandte Chemie (International Ed. in English)|July 25, 2014
Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemiaHua Lu, Quan Zhou, Vishal Deshmukh, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2013
Bispecific small molecule-antibody conjugate targeting prostate cancerChan Hyuk Kim, Jun Y Axup, Brian R Lawson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2008
Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial triggerBen A Croker, Brian R Lawson, Sophie Rutschmann, et al.
Journal of the American Chemical Society|February 21, 2015
An immunosuppressive antibody-drug conjugateRongsheng E Wang, Tao Liu, Ying Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 18, 2006
A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activationYun-Feng Fu, Yi-Na Zhu, Jia Ni, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 6, 2005
S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responsesYun-Feng Fu, Jun-Xia Wang, Yang Zhao, et al.
Nature Immunology|March 2, 2010
An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescenceMichael Berger, Philippe Krebs, Karine Crozat, et al.
Nature|October 11, 2013
A regenerative approach to the treatment of multiple sclerosisVishal A Deshmukh, Virginie Tardif, Costas A Lyssiotis, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical Immunology (Orlando, Fla.)|August 31, 2015
Interleukin-7 is required for CD4(+) T cell activation and autoimmune neuroinflammationBrian R Lawson, Rosana Gonzalez-Quintial, Theodoros Eleftheriadis, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2009
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupusDwight H Kono, M Katarina Haraldsson, Brian R Lawson, et al.
Angewandte Chemie (International Ed. in English)|July 25, 2014
Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemiaHua Lu, Quan Zhou, Vishal Deshmukh, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2013
Bispecific small molecule-antibody conjugate targeting prostate cancerChan Hyuk Kim, Jun Y Axup, Brian R Lawson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2008
Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial triggerBen A Croker, Brian R Lawson, Sophie Rutschmann, et al.
Journal of the American Chemical Society|February 21, 2015
An immunosuppressive antibody-drug conjugateRongsheng E Wang, Tao Liu, Ying Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 18, 2006
A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activationYun-Feng Fu, Yi-Na Zhu, Jia Ni, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 6, 2005
S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responsesYun-Feng Fu, Jun-Xia Wang, Yang Zhao, et al.
Nature Immunology|March 2, 2010
An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescenceMichael Berger, Philippe Krebs, Karine Crozat, et al.
Nature|October 11, 2013
A regenerative approach to the treatment of multiple sclerosisVishal A Deshmukh, Virginie Tardif, Costas A Lyssiotis, et al.
Pageof 4